On 27 February 2025, the first conference on Top Trends in Life Sciences, organised by the DZP Law Firm, was held in Warsaw. Our aim was to create a space for the exchange of experiences and views for leaders of the pharmaceutical market and representatives of the public administration involved in the healthcare sector. We realised that the dynamically changing legal environment that we face in the pharmaceutical sector calls for a broad expert discussion encompassing the perspectives of lawyers, the business community and regulators, as only then can real changes in the shaping of medicine and regulatory policy be achieved. The purpose of the event was also to create a forum for open dialogue on key legal and regulatory changes affecting the pharmaceutical sector.

The conference programme featured a number of speeches and panel discussions:

• keynote speech by the President of the Office for the Registration of Medicinal Products, Medical Devices and Biocidal Products, Dr Grzegorz Cessak, who discussed the EU’s regulatory strategy and the priorities of the Polish presidency of the Council of the European Union,
• presentation by the President of the Personal Data Protection Office, Mirosław Wróblewski, on the role of the GDPR and data protection challenges in the context of the development of artificial intelligence,
• speech by Ludmila Scrine, Chief Medical Officer at Theramex, and Richard Gane, Vice President of Astellas, who talked about the role of in-house lawyers in pharmaceutical firms.

In the next part of the conference, we listened to some very interesting speeches by Katarzyna Piotrowska-Radziewicz from the Ministry of Health, Maria Owczarek from the Personal Data Protection Office and Katarzyna Postek-Kaczmarczyk from the Office for the Registration of Medicinal Products, Medical Devices and Biocidal Products. The meeting ended with a panel discussion on the role of in-house lawyers in pharmaceutical firms, which I had the pleasure of moderating and in which the following people took part: Natalia Łojko (AstraZeneca), Wojciech Tomkiewicz (Adamed), Agnieszka Deeg-Tyburska (Polpharma), Przemysław Bukowy (Amgen) and Dominik Frączek (Biofarm).

One of the important issues we addressed during the event was the role of in-house lawyer in pharmaceutical firms and their influence on strategic business decisions. The panellists emphasised the importance of having the ability to balance regulatory requirements and dynamic business needs, as well as the necessity of taking a proactive approach to impending legislative changes. There was also ample opportunity to discuss new technologies and their impact on the pharmaceutical sector. Particular attention was paid to regulations on artificial intelligence, personal data protection and the implementation of the European Health Data Space (EHDS). Experts stressed the need for adequate mechanisms to protect patient privacy, while supporting innovation and access to data for clinical research.

A summary of the changes is available in the attached PDF file.

To receive the full version of the report, please fill out the form.

More information about the conference - https://toptrendylifesciences.dzp.pl/.